cyclopropanecarboxylic acid [4-(6-ethyl-pyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)-isothiazol-5-yl]-amide hydrochloride | 1189746-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: cyclopropanecarboxylic acid [4-(6-ethyl-pyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)-isothiazol-5-yl]-amide hydrochloride
• 英文别名: N-[4-(6-ethylpyridin-2-yl)-3-(2-methylindazol-5-yl)-1,2-thiazol-5-yl]cyclopropanecarboxamide;hydrochloride
• CAS: 1189746-21-1
• 化学式: C₂₂H₂₁N₅OS*ClH
• 分子量: 439.969
• InChiKey: SOQUGTUMCHFBQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.09
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-甲基-2H-吲唑-5-硼酸频那醇酯 在 bis-triphenylphosphine-palladium(II) chloride 、 二(三叔丁基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 生成 cyclopropanecarboxylic acid [4-(6-ethyl-pyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)-isothiazol-5-yl]-amide hydrochloride
  参考文献：
  名称：

  Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator

  摘要：

  A novel series of selective negative allosteric modulators (NAMs) for metabotropic glutamate receptor 5 (mGlu5) was discovered from an isothiazole scaffold. One compound of this series, (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide (24), demonstrated satisfactory pharmacokinetic properties and, following oral dosing in rats, produced dose-dependent and long-lasting mGlu5 receptor occupancy. Consistent with the hypothesis that blockade of mGlu5 receptors will produce analgesic effects in mammals, compound 24 produced a dose-dependent reduction in paw licking responses in the formalin model of persistent pain. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.009

文献信息

• 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES
  申请人：Britton Thomas Charles

  公开号：US20090253750A1

  公开（公告）日：2009-10-08

  The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

  本发明提供3-吲哚基-4-吡啶基异噻唑或其药用可接受的盐，以及其药物组合物，并使用方法，以及制备方法和中间体。
• US7932274B2
  申请人：——

  公开号：US7932274B2

  公开（公告）日：2011-04-26
• Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator
  作者：Junliang Hao、Veronique Dehlinger、Adam M. Fivush、Helene C.E. Rudyk、Thomas C. Britton、Sean P. Hollinshead、Benjamin P. Vokits、Barry P. Clark、Steven S. Henry、Steven M. Massey、Langu Peng、Bruce A. Dressman、Beverly A. Heinz、Edda F. Roberts、Mallorie R. Bracey-Walker、Steven Swanson、John T. Catlow、Patrick L. Love、Anita D. Tepool、Steven C. Peters、Rosa Maria A. Simmons、Smriti Iyengar、David L. McKinzie、James A. Monn

  DOI：10.1016/j.bmcl.2013.01.009

  日期：2013.3

  A novel series of selective negative allosteric modulators (NAMs) for metabotropic glutamate receptor 5 (mGlu5) was discovered from an isothiazole scaffold. One compound of this series, (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide (24), demonstrated satisfactory pharmacokinetic properties and, following oral dosing in rats, produced dose-dependent and long-lasting mGlu5 receptor occupancy. Consistent with the hypothesis that blockade of mGlu5 receptors will produce analgesic effects in mammals, compound 24 produced a dose-dependent reduction in paw licking responses in the formalin model of persistent pain. (c) 2013 Elsevier Ltd. All rights reserved.